← All trials
NCT06990399
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2025
- Primary completion
- Feb 28, 2026
- Completion date
- Jul 31, 2027
- First posted
- May 25, 2025
- Last posted
- Sep 10, 2025
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kodiak Sciences IncLead sponsor
- Kodiak Sciences IncOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.